title: Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study.
abstract: BACKGROUND
  In this prospective study, the efficacy and safety of radiotherapy combined with zoledronic acid was evaluated.
  
  
  METHODS
  Breast cancer patients with painful bone metastases were randomized to either high- or reduced-dose radiotherapy. All patients received zoledronic acid (4 mg) every 28 days from the beginning of radiotherapy. Analgesic and pain scores in addition to visual analog score (VAS) for treatment satisfaction and whole-body bone scintigraphy were evaluated.
  
  
  CONCLUSIONS
  No significant differences could be found in analgesic or pain scores and bone scintigraphy results between the groups. Our results suggest that reduced-dose radiotherapy produces similar response rates and response durations when used concomitantly with zoledronic acid.
authors.affiliation: Department of Radiation Oncology, Hacettepe University, Ankara 06100, Turkey.
authors.forename: Lale
authors.initials: L
authors.lastname: Atahan
authors.forename: Ferah
authors.initials: F
authors.lastname: Yildiz
authors.forename: Mustafa
authors.initials: M
authors.lastname: Cengiz
authors.forename: Bunyamin
authors.initials: B
authors.lastname: Kaplan
authors.forename: Metin
authors.initials: M
authors.lastname: Ozkan
authors.forename: Gozde
authors.initials: G
authors.lastname: Yazici
authors.forename: Mete
authors.initials: M
authors.lastname: Gündoğ
authors.forename: Ayfer
authors.initials: A
authors.lastname: Haydaroğlu
authors.forename: Aylin F
authors.initials: AF
authors.lastname: Korcum
authors.forename: Meriç
authors.initials: M
authors.lastname: Sengöz
authors.forename: Maktav
authors.initials: M
authors.lastname: Dinçer
authors.forename: Müge
authors.initials: M
authors.lastname: Akmansu
authors.forename: Kayihan
authors.initials: K
authors.lastname: Engin
authors.forename: Mutlu
authors.initials: M
authors.lastname: Hayran
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D010147:Pain Measurement; D010166:Palliative Care; D011879:Radiotherapy Dosage; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid